Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Reviewer: Eric Shinohara, MD, MSCI
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 28 de enero del 2007

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Intraperitoneal Chemo Offers Lasting Benefit in Ovarian Cancer

Mar 26, 2015

Risk of death decreases by 12 percent for every IP chemotherapy cycle completed

Intraperitoneal Chemotherapy Ups Ovarian Cancer Outcomes

Aug 5, 2015

However, only 41 percent of suitable candidates actually receive the therapy

Adjuvant Bevacizumab Feasible in Ovarian Cancer

Nov 10, 2011

Progression-free survival similar to IP, IV therapy; higher risk of bowel perforation/obstruction